Invokana

Invokana (canagliflozin) is an oral medication used to manage blood sugar levels in adults with type 2 diabetes. It belongs to the class of drugs known as sodium-glucose cotransporter 2 (SGLT2) inhibitors. In addition to improving glycemic control, Invokana has been shown to provide cardiovascular and kidney protective benefits in high-risk patients. It is not recommended for the treatment of type 1 diabetes or diabetic ketoacidosis.

Invokana blocks the SGLT2 protein in the kidneys, which typically reabsorbs glucose into the bloodstream. By inhibiting this protein, more glucose is excreted through urine, lowering blood sugar levels. This mechanism is independent of insulin, making it useful in various stages of diabetes. Additionally, it may promote modest weight loss and lower blood pressure in some patients.

Invokana is typically taken once daily before the first meal of the day. It should be swallowed whole with water. Dosage may vary based on kidney function, other medications, and individual response, so following your doctor’s instructions is essential. Your doctor may adjust the dose based on your blood sugar levels and kidney performance.

Invokana may increase the risk of urinary tract infections, genital yeast infections, and dehydration, especially in older adults. There is also a rare but serious risk of diabetic ketoacidosis (DKA), even in people with normal blood sugar levels. It may cause a drop in blood pressure, so individuals taking blood pressure medications should be monitored closely. Patients with kidney disease may require dose adjustments or may not be eligible for treatment.

Common side effects include increased urination, thirst, and risk of genital fungal infections. Other possible effects are fatigue, low blood pressure, and changes in kidney function. In rare cases, it may lead to bone fractures or serious urinary tract infections. Report any unusual symptoms such as abdominal pain, nausea, or confusion promptly to your healthcare provider.